Pradžia › Inksto nepakankamumas › Pennsylvania
Inksto nepakankamumas klinikiniai tyrimai Pennsylvania
7 tyrimai dėl Inksto nepakankamumas ieško dalyvių vietose Pennsylvania.
Miestai Pennsylvania
Oficialus tyrimo tekstas (anglų kalba)
Combined Dose-Finding and CV Outcomes Study With CSL300 (Clazakizumab) in Adult Subjects With ESKD Undergoing Dialysis (POSIBIL6ESKD)
- Northeast Clinical Research Center, LLC, Bethlehem
- Clinical Renal Associates, LTD, Exton
Renkami dalyviai2/3 fazė
Amžius 18 ir vyresni · Visoms lytims · Atnaujinta 2026-09-21 · NCT05485961A Study to Evaluate AZD7760 Safety and Pharmacokinetics in Healthy Adults (Phase I) and Adults With End-stage Kidney Disease on Hemodialysis With a Central Venous Catheter (Phase IIa)
- Research Site, Bethlehem
Renkami dalyviai1/2 fazėLaukiami sveiki savanoriai
Amžius nuo 18 iki 55 · Visoms lytims · Atnaujinta 2026-08-14 · NCT06749457Post-market Surveillance Study of the BD® WavelinQ™ EndoAVF System
- Butler Memorial Hospital, Butler
Renkami dalyviai
Amžius 18 ir vyresni · Visoms lytims · Atnaujinta 2026-08-10 · NCT04634916Virtual Reality in End Stage Kidney Disease
- University of Pennsylvania, Philadelphia
Renkami dalyviai
Visi amžiai · Visoms lytims · Atnaujinta 2026-07-10 · NCT06356168PReSeRVE-HD: Observational Study of the Merit HeRO® Graft and Super HeRO® in Patients on Hemodialysis
- University Pittsburgh Medical Center, Pittsburgh
Renkami dalyviaiStebimasis tyrimas
Amžius 18 ir vyresni · Visoms lytims · Atnaujinta 2026-06-01 · NCT06422871Kidney Transplant Improvement Through New Exercise Training to Increase Capacity
- Perelman Center for Advanced Medicine, Philadelphia
Renkami dalyviai
Amžius 60 ir vyresni · Visoms lytims · Atnaujinta 2026-05-06 · NCT07446296A Study to Evaluate the Safety and Effectiveness of the InnAVasc Arteriovenous Graft for Hemodialysis Access in Patients With End-Stage Renal Disease
- Guthrie Clinic, Sayre
Renkami dalyviai
Amžius nuo 18 iki 90 · Visoms lytims · Atnaujinta 2025-12-22 · NCT04671771Iš ClinicalTrials.gov, duomenys gauti 2026-10-04. Kiekvienas tyrimas nustato savo tinkamumo kriterijus; tyrimo komanda sprendžia, kas gali dalyvauti.